Global Soliris (Eculizumab) Market Growth (Status and Outlook) 2025-2031

Global Soliris (Eculizumab) Market Growth (Status and Outlook) 2025-2031

The global Soliris (Eculizumab) market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.

In Asia-Pacific, Japan is the largest Soliris (Eculizumab) market with about 32% market share. China is follower, accounting for about 25% market share.The key manufacturers are Alexion etc.

LPI (LP Information)' newest research report, the “Soliris (Eculizumab) Industry Forecast” looks at past sales and reviews total world Soliris (Eculizumab) sales in 2024, providing a comprehensive analysis by region and market sector of projected Soliris (Eculizumab) sales for 2025 through 2031. With Soliris (Eculizumab) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Soliris (Eculizumab) industry.

This Insight Report provides a comprehensive analysis of the global Soliris (Eculizumab) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Soliris (Eculizumab) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Soliris (Eculizumab) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Soliris (Eculizumab) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Soliris (Eculizumab).

This report presents a comprehensive overview, market shares, and growth opportunities of Soliris (Eculizumab) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Plasma Exchange
Plasma Infusion

Segmentation by Application:
PNH
aHUS
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alexion